Wegovy weight loss sustained for four years in trial, Novo Nordisk says
Patients taking Novo Nordisk's popular Wegovy obesity treatment maintained an average of 10 per cent weight loss after four years on the treatment, the company said on Tuesday.
Patients taking Novo Nordisk's popular Wegovy obesity treatment maintained an average of 10 per cent weight loss after four years on the treatment, the company said on Tuesday.
New research out of London, Ont.'s Western University is shedding light on a potential cure for ALS, in which the targeting of the interaction between two proteins can halt or fully reverse the disease's progression.
A new study projecting declining rates of cancer cases and deaths in Canada demonstrates the success of prevention and early detection programs, but also highlights areas where more work is needed to save and prolong lives, researchers say.